Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045136 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 1 study, sponsored by Poniard Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00045136: Completed Phase 1 study, sponsored by Poniard Pharmaceuticals.
NCT00045136 is a Phase 1 study that has completed, run by Poniard Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045136, a Phase 1 study, has completed, sponsored by Poniard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer cells and cause less damage to normal tissue. Combining chemotherapy and holmium Ho 166 DOTMP with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and holmium Ho 166 DOTMP and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining holmium Ho 166 DOTMP with melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.
Interventions
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- RADIATION holmium Ho 166 DOTMP
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Phase | Phase 1 |
What the finished NCT00045136 record still lists
NCT00045136 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which melphalan is the first listed.
NCT00045136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045136 about?
NCT00045136 is a clinical study titled "Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer cells and cause less damage to normal tissue. Combining chemotherapy and holmium Ho 166 DOTMP with peripheral stem ce...
What is the current status of trial NCT00045136?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01.
What interventions are being tested in trial NCT00045136?
The interventions under investigation include: melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), holmium Ho 166 DOTMP (RADIATION).
Who is sponsoring clinical trial NCT00045136?
This trial is sponsored by Poniard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia